Investment Thesis
Autolus is a pre-commercial or early-stage biopharmaceutical company with minimal revenue relative to operating expenses, resulting in severe operating losses and negative free cash flow of -$236.2M. While strong liquidity metrics (6.19x current ratio) provide a near-term runway, the company is burning cash at an unsustainable rate and faces fundamental questions about commercialization success and path to profitability.
Strengths
- Strong liquidity position with $86.1M cash and 6.19x current ratio providing operational runway
- Dramatic revenue growth of +496% YoY indicating successful product commercialization or launch
- Zero long-term debt and low leverage (0.00x debt-to-equity) reduces financial distress risk
Risks
- Severe cash burn of -$216.2M operating cash flow with negative free cash flow of -$236.2M indicating unsustainable burn rate
- Operating margins of -387.6% and net margins of -385.9% show company is losing $3.86 for every dollar of revenue generated
- EPS of -$0.74 and ROE of -74.3% demonstrate significant losses; current cash runway of approximately 0.4 years at current burn rate
- Early-stage biotech with no gross profit visibility, suggesting revenue insufficient to cover cost of goods sold
Key Metrics to Watch
- Quarterly cash burn rate and months of cash runway remaining
- Revenue growth sustainability and gross margin expansion as commercialization scales
- Operating cash flow trend and pathway to cash flow breakeven
- Funding activities and capital raise requirements
Financial Metrics
Revenue
51.1M
Net Income
-197.2M
EPS (Diluted)
$-0.74
Free Cash Flow
-236.2M
Total Assets
661.9M
Cash
86.1M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-387.6%
Net Margin
-385.9%
ROE
-74.3%
ROA
-29.8%
FCF Margin
-462.2%
Balance Sheet & Liquidity
Current Ratio
6.19x
Quick Ratio
5.86x
Debt/Equity
0.00x
Debt/Assets
59.9%
Interest Coverage
-14.32x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-20T10:34:10.928395 |
Data as of: 2025-09-30 |
Powered by Claude AI